desloratadine / Generic mfg. - LARVOL DELTA

Fixed Drug Eruption Following Concurrent Ciprofloxacin and Metronidazole Therapy: A Dermoscopy-Assisted Diagnosis. (PubMed, Cureus) - "Treatment consisted of systemic corticosteroids (prednisone 20 mg daily for seven days), oral antihistamines (desloratadine 5 mg daily), and topical therapy including fluticasone propionate 0.05% nightly and calamine-based emollients. This report emphasizes the importance of clinical vigilance when prescribing commonly used antibiotics and demonstrates the utility of alternative diagnostic approaches in resource-limited settings. Primary care physicians and dermatologists should maintain awareness of FDE presentations and counsel patients to avoid re-exposure to implicated medications."

Journal • Dermatology • Gastrointestinal Disorder • Immunology

Visinin-like protein 1 disrupts calcium homeostasis and promotes atrial fibrillation in human and rodent models. (PubMed, Signal Transduct Target Ther) - "Pharmacologically, repaglinide and desloratadine, two FDA-approved drugs that identified to target VILIP-1 or its myristoylation, attenuated AF susceptibility by reducing NCX-1 surface expression and restoring intracellular Ca2+ homeostasis. Collectively, our findings define VILIP-1 as a critical upstream modulator of atrial Ca2+ homeostasis and establish it as a promising therapeutic target for AF, with efficacy validated in human and rodent models."

Journal • Preclinical • Atrial Fibrillation • Cardiovascular • VSNL1

Experts' view on the management of scalp seborrheic dermatitis in Italy. (PubMed, J Dermatolog Treat) - "Recent evidence suggests that combining isotretinoin with desloratadine may enhance treatment outcomes. Systemic antifungals may be considered in refractory cases. This experts' view provides a structured approach to SSD management in Italy, integrating clinical experience and scientific evidence."

Journal • Review • Acne Vulgaris • Atopic Dermatitis • Dermatitis • Dermatology • Immunology • Psoriasis • Seborrheic Dermatitis

Autologous Whole Blood Therapy in Chronic Idiopathic Urticaria Patients. (clinicaltrials.gov) - P3 | N=40 | Not yet recruiting | Sponsor: Cairo University

New P3 trial • Chronic Spontaneous Urticaria • Dermatology • Immunology • Urticaria

'Oral isotretinoin plus desloratadine for acne vulgaris: an updated global meta-analysis of efficacy, safety, and patient-centered outcomes'. (PubMed, J Dermatolog Treat) - "Patient satisfaction was greater, with no significant changes observed in laboratory safety parameters. Isotretinoin with desloratadine offers superior efficacy and tolerability, ensuring higher patient satisfaction without safety risks."

Clinical • Journal • Retrospective data • Review • Acne Vulgaris • Dermatology • Pruritus

Case report: Cetirizine-induced fixed drug eruption in a pediatric patient (AAD 2026) - "We discontinued cetirizine, switched to desloratadine, and educated them about FDE. The final diagnosis was FDE due to cetirizine. This is the first case of FDE caused by cetirizine in a pediatric patient."

Case report • Clinical • Allergic Rhinitis • Immunology • Inflammation • Pediatrics • Pruritus

Investigation of the impacts of second-generation antihistamines on free-living marine nematodes and their interaction with ZnS nanoparticles: Mechanistic insights from community and population approaches and molecular interactions modeling. (PubMed, Mar Environ Res) - "Overall, the findings suggest synergistic or additive interaction between loratadine, desloratadine, and ZnS nanoparticles. Their toxicokinetic properties, along with strong binding affinities and stable molecular interactions with GLD-3 and SDP receptors, provide a mechanistic basis and support ecotoxicological impacts of these antihistamines and ZnS NPs on nematodes."

Journal • CAT

The effects of oral second-generation antihistamines on psychomotor, cognitive, and academic performance: A systematic review (AAAAI 2026) - "Search terms included oral second-generation antihistamines approved for use in the United States and Canada, specifically cetirizine, loratadine, fexofenadine, desloratadine, levocetirizine, bilastine, and rupatadine, with the terms psychomotor, cognitive, and academic performance. Varying effects were found across these categories. Understanding these outcomes will better inform patient care via appropriate selection of antihistamines to minimize disruption on daily activities."

Review

299IG301: A Study to Learn About the Effects of Felzartamab Infusions on Adults With Immunoglobulin A Nephropathy (IgAN) ( PREVAIL ) (clinicaltrialsregister.eu) - P2/3 | N=201 | Recruiting | Sponsor: Biogen Idec Research Limited

New P2/3 trial • Glomerulonephritis • IgA Nephropathy • Renal Disease

A clinical trial to evaluate the efficacy and safety of a mixture of allergenic extracts of D. pteronyssinus and D. farinae, in patients suffering from allergic rhinoconjunctivitis with or without controlled asthma (clinicaltrialsregister.eu) - P2/3 | N=320 | Not yet recruiting | Sponsor: LETI Pharma S.L.U.

New P2/3 trial • Asthma • Conjunctivitis • Immunology • Ocular Infections • Ocular Inflammation • Ophthalmology • Pulmonary Disease • Respiratory Diseases

DETOXp: Desloratadine to Prevent Taxane-induced Peripheral Neuropathy in Patients With Breast Cancer (clinicaltrials.gov) - P2 | N=116 | Not yet recruiting | Sponsor: Montefiore Medical Center | Trial completion date: Mar 2030 ➔ Jun 2030 | Trial primary completion date: Mar 2029 ➔ Jun 2029

Trial completion date • Trial primary completion date • Breast Cancer • Oncology • Pain • Solid Tumor

Risk of injury associated with the sedative potential of second-generation antihistamines: A nationwide retrospective cohort study. (PubMed, Br J Clin Pharmacol) - "In this large nationwide cohort of patients with allergic rhinitis, second-generation antihistamines with higher vs. lower sedative potential showed no difference in injury risk during Japan's pollen season."

Journal • Retrospective data • Allergic Rhinitis • Anesthesia • Immunology • Inflammation

Synergistic cell membrane-coated ECL-DNA biosensor for specificity-enhanced drug lead evaluation. (PubMed, J Pharm Anal) - "Using this approach, we demonstrated a linear dynamic range of 1 nmol/L to 2 μmol/L for the detection of desloratadine activity, with a limit of detection (LOD) of 0.16 nmol/L. Furthermore, the platform was successfully applied to evaluate the binding activity of eight drugs to angiotensin-converting enzyme 2 (ACE2), and their pharmacological activities were further characterized. Overall, this aptamer-cell membrane coating synergistic strategy offered excellent specificity and ultra-high sensitivity, making it a valuable tool for elucidating drug-receptor mechanisms of action and providing a robust reference for preclinical drug activity evaluation."

Journal

Exploring C5AR1 gene variants (rs11673309) and their impact on clinical features of chronic spontaneous urticaria. (PubMed, Dermatol Reports) - "Furthermore, patients with the TG genotype required a higher dose of desloratadine (p<0.001). Patients with the TG genotype experienced lower quality of life, emphasizing the need for proactive management. These findings contribute to understanding the genetic basis of CSU in Vietnamese patients."

Journal • Chronic Spontaneous Urticaria • Dermatology • Immunology • Urticaria • C5AR1

UC: Desloratadine in Patients With Ulcerative Colitis (clinicaltrials.gov) - P2 | N=44 | Recruiting | Sponsor: Tanta University | Not yet recruiting ➔ Recruiting

Enrollment open • Gastroenterology • Gastrointestinal Disorder • Immunology • Inflammatory Bowel Disease • Ulcerative Colitis

Comparison of aprepitant versus desloratadine for EGFR-TKI-induced pruritus: A randomized phase 2 clinical trial. (PubMed, Cancer) - P2 | "To the authors' knowledge, this is the first study to prospectively present that aprepitant elicited a better and faster response and mild toxicity for managing EGFR-TKI induced pruritus than desloratadine."

Clinical • Journal • P2 data • Constipation • Dermatology • Gastroenterology • Gastrointestinal Disorder • Lung Cancer • Non Small Cell Lung Cancer • Oncology • Pruritus • Solid Tumor • Xerostomia • EGFR

Administration of Desloratadine for Postorgasmic Illness Syndrome in a Japanese Teenager. (PubMed, IJU Case Rep) - "A Japanese teenager suffering from postorgasmic illness syndrome was successfully treated with desloratadine. We believe that our experience will contribute to elucidating and treating this condition in the future."

Journal • CNS Disorders • Depression • Fatigue • Pain • Psychiatry

Optical control of H1 receptor signaling with a BODIPY-photocaged antihistamine. (PubMed, Biochem Pharmacol) - "Irradiation of 1 with 560 nm light results in photo-uncaging and the release of the parent drug desloratadine, resulting in optical modulation of histamine-induced H1R signaling. The presented BODIPY-based photocaging of desloratadine offers a powerful new tool for the precise optical control of H1R function."

Journal • Allergy

UC: Desloratadine in Patients With Ulcerative Colitis (clinicaltrials.gov) - P2 | N=44 | Not yet recruiting | Sponsor: Tanta University

New P2 trial • Gastroenterology • Gastrointestinal Disorder • Immunology • Inflammatory Bowel Disease • Ulcerative Colitis

Efficacy of a Combination Therapy of Montelukast and Antihistamines in Allergic Rhinitis: A Systematic Review and Network Meta-Analysis. (PubMed, Allergy Asthma Immunol Res) - "The treatment strategies included montelukast alone, antihistamine monotherapies (loratadine, desloratadine, levocetirizine, and fexofenadine), their respective combinations with montelukast, including bilastine. Although some comparisons require cautious interpretation, montelukast-based combination therapy demonstrated greater efficacy than monotherapy for multiple AR symptoms. These results highlight the importance of selecting therapeutic strategies based on the predominant symptom profile of individual patients."

Journal • Retrospective data • Review • Allergic Rhinitis • Conjunctivitis • Immunology • Inflammation • Ocular Infections • Ocular Inflammation • Ophthalmology

Investigation of the Immune System Effects of Desloratadine on Lipopolysaccharide-Stimulated Mammalian Macrophage Cells. (PubMed, Fundam Clin Pharmacol) - "DES selectively modulates macrophage responses, strongly inhibiting TNF-α and IL-12p40 while enhancing GM-CSF, reflecting a dual anti- and pro-inflammatory profile. These findings support further investigation of DES in neuroinflammatory and immune-mediated conditions."

Journal • CNS Disorders • Immunology • Inflammation • IL6 • TNFA

Desloratadine Induces TP53-Dependent Apoptosis in MCF-7 Breast Cancer Cells. (PubMed, Cells) - "Compared with wild-type cells, these knockout cells displayed markedly reduced sensitivity to Desloratadine, with the IC50 shifting from 14.2 µg/mL to 36.4 µg/mL, demonstrating that p53 is a key mediator of the drug's cytotoxic effect. Collectively, these findings identify Desloratadine as a potential repurposed drug candidate for breast cancer therapy, acting at least in part through a p53-dependent apoptotic pathway."

IO biomarker • Journal • Breast Cancer • Oncology • Solid Tumor • ANXA5 • BCL2 • PARP1 • STAT3 • TP53

Differential modulation of cisplatin efficacy by montelukast sodium and desloratadine in lung cancer. (PubMed, Turk J Biol) - "These findings support the potential of MLS as an effective adjuvant in CIS-based lung cancer treatment. However, the antagonistic effect observed with DES highlights the importance of careful evaluation of candidates for drug repurposing."

Journal • Lung Cancer • Oncology • Solid Tumor • GPX4

Impact of Desloratadine on Treatment Response and Inflammation During Neoadjuvant Chemotherapy in Stage II-III Breast Cancer: A Randomized Pilot Study. (PubMed, Arch Med Res) - "Desloratadine may improve treatment response in stage III breast cancer, supporting its potential role as a complementary agent in neoadjuvant chemotherapy."

Journal • Allergy • Breast Cancer • Immunology • Oncology • Solid Tumor • IL6 • NFKB1 • TLR4 • TNFA

Comparing Antihistamines for Chronic Urticaria: Systematic Review Dose Response and Network Meta-Analysis of Randomized Trials (ACAAI 2025) - "Sedation likely increases with higher doses, with first-generation agents among the most sedating; cetirizine, ketotifen, levocetirizine, and rupatadine among the intermediate sedating; and bilastine, desloratadine, fexofenadine, and loratadine among the least sedating. Cetirizine and loratadine are among the most effective for all components of urticaria activity, but cetirizine is intermediately sedating and loratadine has lower certainty on improving quality of life and sleep. Higher doses may have diminishing benefits and increased risks."

Retrospective data • Review • Anesthesia • Cardiovascular • CNS Disorders • Dermatology • Immunology • Pruritus • Sleep Disorder • Urticaria